Skip to content

Desensitization and Cognitive Therapy in General Anxiety.

Desensitization and Cognitive Therapy in General Anxiety.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00951340
Enrollment
21
Registered
2009-08-04
Start date
1996-07-31
Completion date
1998-12-31
Last updated
2017-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Keywords

CBT, Emotional-Focused Therapy, Interpersonal Therapy

Brief summary

This study will test the feasibility and safety of adding interpersonal and emotional processing techniques to standard cognitive behavioral therapy for generalized anxiety disorder.

Detailed description

Generalized anxiety disorder (GAD) is characterized by chronic worry that interrupts normal functioning. Some research has shown cognitive behavioral therapy (CBT) as an effective treatment for GAD, but only half of people treated with CBT for GAD experience treatment benefits long-term. Standard CBT for GAD may lose effectiveness over time because it does not address interpersonal and emotional processing problems. This study will determine the safety and feasibility of training therapists to deliver a version of CBT with additional therapeutic techniques for addressing interpersonal interactions and emotional processing. Participation in this study will include 14 weekly, 2-hour, individual therapy sessions. During the first hour of each session, all participants will receive standard CBT for GAD. Participants will be randomly assigned to receive one of two therapies during the second hour: training in interpersonal and emotional processing techniques or listening therapy. Participants taking medications will be required to maintain a fixed dosage and keep a daily dairy of medication use, starting 2 weeks before study entry and lasting throughout treatment. In-depth study assessments will take place at baseline and after completing the 15 weeks of therapy. Assessments will include clinical interviews, self-report questionnaires, and a physiological measurement session. Questions will pertain to anxiety symptoms, self-perceptions, emotional experience, and perceptions of the world. The physiological measurement session will involve recording bodily reactions, including brain waves, heart rate, eye movement, and breathing, while performing simple perceptual tasks. Brief psychological assessments will also follow each hour-long portion of each therapy session. Follow-up assessments conducted 6, 12, and 24 months after completing treatment will involve interviews and questionnaires as well as recording a week's worth of medication diaries.

Interventions

OTHERCognitive behavioral therapy (CBT)

15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques

BEHAVIORALEmotional processing and interpersonal therapy

15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques

BEHAVIORALListening therapy

15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Penn State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* Principal diagnosis of generalized anxiety disorder (GAD), as defined by the DSM-IV and agreed on by two diagnostic interviewers

Exclusion criteria

* Concurrent psychosocial therapy or past adequate dosage of CBT * Medical contributions to anxiety * Current substance abuse, psychosis, or organic brain syndrome

Design outcomes

Primary

MeasureTime frame
Feasibility of delivering emotional processing and interpersonal therapeutic techniquesMeasured at baseline, post-treatment, and after 6, 12, and 24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026